Details of the Drug

General Information of Drug (ID: DMF6Z5T)

• Drug Name: Glecaprevir; pibrentasvir
• Synonyms: pibrentasvir; Maviret; Mavyret; Glecaprevir / pibrentasvir; Glecaprevir and pibrentasvir; ABT-493/ABT-530; Glecaprevir mixture with pibrentasvir; ABT-493 / ABT-530; S900007520

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Approved	[1]

• ATC Code:
  J05AP57: Glecaprevir; pibrentasvir
  J05AP: Antivirals for treatment of HCV infections
  J05A: DIRECT ACTING ANTIVIRALS
  J05: ANTIVIRALS FOR SYSTEMIC USE
  J: ANTIINFECTIVES FOR SYSTEMIC USE
• Drug Type: Combination drug
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 110 mcg/L []
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 h []
  Elimination: 96.6% of administered drug is excreted in feces []
  Half-life: The concentration or amount of drug in body reduced by one-half in 13 hours []
  Metabolism: The drug is not metabolised []
• Cross-matching ID: TTD ID: D0C4DH

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus Non-structural 5A (HCV NS5A)	TTCJ2X8	POLG_HCV1	Inhibitor	[1]
Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)	TTHC7JD	POLG_HCV1	Inhibitor	[1]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.